- Home
- ELDN
as 12-20-2024 3:35pm EST
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 239.6M | IPO Year: | N/A |
| Target Price: | $16.00 | AVG Volume (30 days): | 553.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.43 - $5.54 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Eledon Pharmaceuticals Inc. News
ELDN Breaking Stock News: Dive into ELDN Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions
GlobeNewswire
a month ago
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
GlobeNewswire
2 months ago
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
GlobeNewswire
2 months ago
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
2 months ago
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
GlobeNewswire
3 months ago
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
GlobeNewswire
4 months ago
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
GlobeNewswire
4 months ago
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Compare ELDN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELDN Eledon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.